Evidence map›Paper›PMID 31638686›Full record

ReviewJAMA2019

Diagnosis and Management of Dementia: Review.

Zoe Arvanitakis, Raj C Shah, David A Bennett

Registry-linked trialOpen access · greenAbstract readReview
In one paragraph

Review in JAMA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05475158 (Comparison of Optical Coherence Tomography Angiographic Factors of Macula and Optic Disc in Patients With or Without Amyloid Pathology), which is not on this map. Cited by 642 papers, 24 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
642citing papers in PubMed, 24 pooled it
79.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05475158 completednot on this map

Comparison of Optical Coherence Tomography Angiographic Factors of Macula and Optic Disc in Patients With or Without Amyloid Pathology: A Prospective Study

TypeobservationalSponsorPusan National University HospitalRan2019 to 2021Enrolled117ConditionsAlzheimer Disease, Amyloid Angiopathy, Macular Ischemia, Dementia
3 · Its place in the literature

Who cites it

642 citing papers in PubMed, 24 syntheses or guidelines pooled it, 1,359 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Association between higher serum uric acid levels and cognitive function: a systematic review and meta-analysis.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025
    Pooled it
  11. Pooled it
  12. Visual field defects in dementia: A scoping review.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2025
    Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Guideline
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

582 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Zoe ArvanitakisRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.
Raj C ShahRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.
David A BennettRush Alzheimer's Disease Center, Rush University Medical Center, Chicago, Illinois.
University of Illinois Chicago · USRush University Medical Center · US

Funding

SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1991 to 2020
$49.1M
Linking peripheral and brain insulin resistance to AD neuropathology and cognitionRF1AG059621 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI AHIMA, REXFORD S., ARNOLD, STEVEN E · 2018 to 2018
$3.8M
Mechanisms linking insulin resistance to brain structure, pathology, and functionR01NS084965 · NINDS · RUSH UNIVERSITY MEDICAL CENTER · PI AHIMA, REXFORD S., ARNOLD, STEVEN E · 2014 to 2018
$3.2M
Vascular Cognitive and Motor Decline: Impact of aPLR01AG040039 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI ARVANITAKIS, ZOE · 2011 to 2015
$2.9M
NIA NIH HHS P30 AG010161NIA NIH HHS R01 AG040039NIA NIH HHS RF1 AG059621NINDS NIH HHS R01 NS084965
6 · The paper itself

Abstract

Importance: Worldwide, 47 million people live with dementia and, by 2050, the number is expected to increase to 131 million. Observations: Dementia is an acquired loss of cognition in multiple cognitive domains sufficiently severe to affect social or occupational function. In the United States, Alzheimer disease, one cause of dementia, affects 5.8 million people. Dementia is commonly associated with more than 1 neuropathology, usually Alzheimer disease with cerebrovascular pathology. Diagnosing dementia requires a history evaluating for cognitive decline and impairment in daily activities, with corroboration from a close friend or family member, in addition to a thorough mental status examination by a clinician to delineate impairments in memory, language, attention, visuospatial cognition such as spatial orientation, executive function, and mood. Brief cognitive impairment screening questionnaires can assist in initiating and organizing the cognitive assessment. However, if the assessment is inconclusive (eg, symptoms present, but normal examination findings), neuropsychological testing can help determine whether dementia is present. Physical examination may help identify the etiology of dementia. For example, focal neurologic abnormalities suggest stroke. Brain neuroimaging may demonstrate structural changes including, but not limited to, focal atrophy, infarcts, and tumor, that may not be identified on physical examination. Additional evaluation with cerebrospinal fluid assays or genetic testing may be considered in atypical dementia cases, such as age of onset younger than 65 years, rapid symptom onset, and/or impairment in multiple cognitive domains but not episodic memory. For treatment, patients may benefit from nonpharmacologic approaches, including cognitively engaging activities such as reading, physical exercise such as walking, and socialization such as family gatherings. Pharmacologic approaches can provide modest symptomatic relief. For Alzheimer disease, this includes an acetylcholinesterase inhibitor such as donepezil for mild to severe dementia, and memantine (used alone or as an add-on therapy) for moderate to severe dementia. Rivastigmine can be used to treat symptomatic Parkinson disease dementia. Conclusions and Relevance: Alzheimer disease currently affects 5.8 million persons in the United States and is a common cause of dementia, which is usually accompanied by other neuropathology, often cerebrovascular disease such as brain infarcts. Causes of dementia can be diagnosed by medical history, cognitive and physical examination, laboratory testing, and brain imaging. Management should include both nonpharmacologic and pharmacologic approaches, although efficacy of available treatments remains limited.

Indexed as

Alzheimer DiseaseCholinesterase InhibitorsDementiaExcitatory Amino Acid AntagonistsHumansMemantineNeuroimagingNeuropsychological TestsCholinesterase InhibitorsExcitatory Amino Acid AntagonistsMemantine

Identifiers

PMID31638686
PMCPMC7462122
OpenAlexW2981624110

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.